We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Currently, new anti-carbapenem-resistant Enterobacteriaceae (CRE) antibiotics are estimated to treat 35 percent of CRE infections in which they were expected to be used as first-line agents...
According to the U.S. Centers for Disease Control and Prevention there are at least two million people in the country who become infected with a bacteria that are resistant to antibiotics